Alexion trials rare disease drug Ultomiris in severe COVID-1...

Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients.

Roche trumpets data for Soliris rival in NMOSD after US, EU ...

Alexion stalks rare disease drug from Stealth with $30m opt-...

/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0;

UCB sets sights on rare diseases giant Alexion with Ra Pharm...

UCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage treatment for the rare muscle weakness disease myasthenia gravis to its R&D pipeline and sett

Roche preps filings for satralizumab in rare disease NMOSD

Alexion’s biosimilar-blocking EU patent play for Soliris fai...